The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

2010 ◽  
Vol 66 (11) ◽  
pp. 1109-1117 ◽  
Author(s):  
Nikolina Jovanović ◽  
Nada Božina ◽  
Mila Lovrić ◽  
Vesna Medved ◽  
Miro Jakovljević ◽  
...  
Keyword(s):  
First Episode ◽  
Drug Naïve ◽  
First Episode Schizophrenia

scholarly journals The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia

2021 ◽  
Vol 12 ◽  
Author(s):  
Xue Li ◽  
Xiaoduo Fan ◽  
Xiuxia Yuan ◽  
Lijuan Pang ◽  
Shaohua Hu ◽  
...  
Keyword(s):  
Treatment Response ◽  
Butyric Acid ◽  
Serum Levels ◽  
First Episode ◽  
Healthy Controls ◽  
Significant Difference ◽  
Drug Naïve ◽  
First Episode Schizophrenia ◽  
Risperidone Treatment

Background: Butyric acid, a major short-chain fatty acid (SCFA), has an important role in the microbiota–gut–brain axis and brain function. This study investigated the role of butyric acid in treatment response in drug-naïve first episode schizophrenia.Methods: The study recruited 56 Chinese Han schizophrenia inpatients with normal body weight and 35 healthy controls. Serum levels of butyric acid were measured using Gas Chromatography-Mass Spectrometer (GC-MS) analysis at baseline (for all participants) and 24 weeks after risperidone treatment (for patients). Clinical symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) for patients at both time points.Results: At baseline, there was no significant difference in serum levels of butyric acid between patients and healthy controls (p = 0.206). However, there was a significant increase in serum levels of butyric acid in schizophrenia patients after 24-week risperidone treatment (p = 0.030). The PANSS total and subscale scores were decreased significantly after 24-week risperidone treatment (p's < 0.001). There were positive associations between baseline serum levels of butyric acid and the reduction ratio of the PANSS total and subscale scores after controlling for age, sex, education, and duration of illness (p's < 0.05). Further, there was a positive association between the increase in serum levels of butyric acid and the reduction of the PANSS positive symptoms subscale scores (r = 0.38, p = 0.019) after controlling for potential confounding factors.Conclusions: Increased serum levels of butyric acid might be associated with a favorable treatment response in drug-naïve, first episode schizophrenia. The clinical implications of our findings were discussed.

scholarly journals Abnormalities of EEG Microstates In Drug-Naïve, First-Episode Schizophrenia

2021 ◽  
Author(s):  
Qiaoling Sun ◽  
Linlin Zhao ◽  
Liwen Tan
Keyword(s):  
Clinical Symptoms ◽  
Early Stage ◽  
First Episode ◽  
Healthy Controls ◽  
Brain Functions ◽  
Class D ◽  
Syndrome Scale ◽  
Drug Naïve ◽  
Microstate Analysis ◽  
First Episode Schizophrenia

Abstract Objective: Microstate analysis is a powerful tool to probe the brain functions, and changes in microstates under electroencephalography (EEG) have been repeatedly reported in patients with schizophrenia. This study aimed to investigate the dynamics of EEG microstates in drug-naïve, first-episode schizophrenia (FE-SCH) and to test the relationship between EEG microstates and clinical symptoms.Methods: Resting-state EEG were recorded for 23 patients with FE-SCH and 23 healthy controls using a 64-channel cap. Three parameters, i.e., contribution, duration, and occurrence, of the four microstate classes were calculated. Group differences in EEG microstates and their clinical symptoms (assessed using the Positive and Negative Syndrome Scale) were analyzed.Results: Compared with healthy controls, patients with FE-SCH showed increased duration, occurrence and contribution of microstate class C and decreased contribution and occurrence of microstate class D. In addition, the score of positive symptoms in PANSS was negatively correlated with the occurrence of microstate D.Conclusions: Our findings showed abnormal patterns of EEG microstates in drug-naïve, first-episode schizophrenia, which might help distinguish individuals with schizophrenia in the early stage and develop early intervention strategies.

A Pilot Double-Blind, Dose-Comparison Study of Risperidone in Drug-Naive, First-Episode Schizophrenia

2001 ◽  
Vol 62 (12) ◽  
pp. 994-995 ◽  
Author(s):  
Hsien-Yuan Lane ◽  
Wen-Ho Chang ◽  
Chih-Chiang Chiu ◽  
Ming-Chyi Huang ◽  
Sue-Hong Lee ◽  
...  
Keyword(s):  
First Episode ◽  
Comparison Study ◽  
Double Blind ◽  
Dose Comparison ◽  
Drug Naïve ◽  
First Episode Schizophrenia
Sign in / Sign up

Export Citation Format

Share Document